Genmab paused patient enrollment in an early‑stage trial of GEN1286, an oncology candidate acquired through its $1.8 billion purchase of ProfoundBio. The Phase 1/2 study had been planned to enroll about 260 patients but the company suspended new recruitment while it reviews trial data and next steps. Genmab provided limited public detail on the rationale for the pause; such holds can reflect safety reviews, manufacturing hurdles, or strategic reprioritization after an acquisition. The interruption affects the timeline for dose‑finding and efficacy readouts that would validate the asset’s value contribution to Genmab’s pipeline. Analysts and partners will be monitoring Genmab’s communications for clarity on whether the pause is temporary and what remedial actions—protocol amendments, additional monitoring, or new cohorts—might be required.